Jeff Goater, MBA
Jeff Goater is a Venture Partner at The Column Group. Previously, he served as Chief Executive Officer of Surface Oncology from February 2018 to March 2021. Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he led its crossover financing, initial public offering and strategic partnership with Sanofi Genzyme. Previously, Jeff spent nearly a decade in investment banking, most recently as a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist in the field of AAV gene therapy and holds master’s degrees in microbiology/immunology (M.S.), pathology (M.S.) and business administration (M.B.A.) from the University of Rochester. In addition to Surface, Jeff also serves on the boards of Atavistik Bio, Kallyope, LogicBio Therapeutics and Ribon Therapeutics.